RemeGen Co. Ltd. Class H (HK:9995) has released an update.
RemeGen Co., Ltd. has announced positive results from their Phase III clinical trial for Disitamab Vedotin, a treatment for HER2-positive advanced breast cancer with liver metastases, meeting its primary endpoint. The Company is preparing to submit a marketing application for the drug, which has already been granted breakthrough therapy designation. Disitamab Vedotin, the first domestically developed anti-HER2 antibody-drug conjugate in China, has previously received conditional approval for other cancer treatments.
For further insights into HK:9995 stock, check out TipRanks’ Stock Analysis page.
